H Plus Yangji Hospita
Seoul, South Korea
NCT Number: NCT07538466
A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232
Trial opening soon.
Get Notified19 year and older
All sexes
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AD-123 Oral Tablet
AD-1231 Oral Tablet + AD-1232 Oral Tablet
Time frame: pre-dose to 72 hours
Cmax of AD-123
Time frame: pre-dose to 72 hours
AUCt of AD-123
Contact information is provided by the study sponsor or research team.
Addpharma Inc.
Industry
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 in Healthy Adult Volunteers Under Fasting Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07045298
Cardiovascular Diseases, Diabetes Mellitus
Atlanta, Georgia, United States
View Trial DetailsNCT07705958
Balance, Diabetes Mellitus
View Trial DetailsNCT07696910
Diabetes Mellitus, Endocrine System Diseases
View Trial DetailsNCT07665775
Arterial Occlusive Diseases, Arteriosclerosis
Mexico City, Mexico
View Trial Details